Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

ficacy assessments for each participant were based on the American College of Rheumatology criteria, which denotes at least a 20% (ACR 20) improvement, at least a 50% (ACR 50) improvement, or at least a 70% (ACR 70) improvement, from the baseline assessment at the end of the 3 month treatment period. The ACR measurement factors included reported physician and patient global assessment of disease activity, patient reported pain score, and any change in CRP in the patient's blood. The primary efficacy endpoint for the clinical trial was the percent of patients assigned to the R788 100 mg bid dose who were ACR 20 responders at the end of 3 months. Secondary efficacy endpoints included other ACR scores and, a comparison of response rates for the R788 100 mg bid dose versus placebo as determined by MRI using the modified RAMRIS scoring system of wrists and hands at baseline and at month 3.

R788 and RA

RA is a progressive, painful and potentially debilitating disease, that affects more than 2 million people in the U.S. It is a chronic inflammatory disease that puts the body's immune system into overdrive where it ultimately causes inflammation in the joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point of inflammation, thereby stopping the progression of the disease. In July 2009, Rigel announced results from its Phase 2b TASKi2 clinical trial showing significant improvement in RA patients treated with R788 who had failed to respond to methotrexate treatment.

Conference Call and Webcast Information

Rigel will host a conference call to discuss the R788 TASKi3 Phase 2b clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters today, July 23, 2009, at 7:00 pm EDT/ 4:00 pm PDT. A presentation related to the TASKi3
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... first quarter ended March 31, 2015 and provided a ... equity offering in February, which raised net proceeds ... strong financial position to advance our lead pipeline ...
(Date:5/4/2015)... 4, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... provided a regulatory update on Zalviso and reported ... 31, 2015. Zalviso Regulatory UpdateOn April ... Division of Anesthesia, Analgesia, and Addiction Products (DAAAP ...
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 3AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 4AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 6AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 7AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 8Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3
... is pleased to announce the addition of Suzie Williams , CP as ... Regional Clinical Manager.   , , ... http://www.newscom.com/cgi-bin/prnh/20100427/DA94114 ) , , , ... Suzie will be joining us as we were not only impressed by her ...
... & Reed Global Executive Search, a growing recruiting firm with offices worldwide, ... of Managing Director, Biopharmaceutical Life Sciences, effective April 15, 2010 . ... "Dave has outstanding ... recognize how important it is for our clients to work with a ...
Cached Medicine Technology:Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager 2Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences 2
(Date:5/4/2015)... 2015 Every Friday afternoon at A ... in Southwest Michigan, patients and staff gather in the ... the rehabilitation program and to gain encouragement and inspiration ... , One by one, those patients who have completed ... their certificates and to share a bit about their ...
(Date:5/4/2015)... UK (PRWEB) May 04, 2015 During ... witness a 7.7% CAGR. Currently, the European and APAC ... world, while the North American probiotic market lags behind ... local population. , The North American probiotic market ... over 58%), followed by Canada and Mexico. The North ...
(Date:5/4/2015)... 04, 2015 The American Council ... Thomopulos, P.E., Chairman of Stanley Consultants , to ... of directors for a three-year term. , ACEC co-established ... the American Society of Civil Engineers (ASCE). A ... system for civil infrastructure called Envision. Launched in 2012, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Global ... innovative proofreading technologies, today announced that it will ... the Music City Center, in Nashville Tennessee, May ... the world's first true all-in-one we-based packaging inspection ... in the security of their brand copy and ...
(Date:5/4/2015)... Malibu Biotech Systems LLC salutes ... KissSafe™ is the first personal hygiene product dedicated ... adding fresh breath appeal. KissSafe™ contains an FDA-approved ... in the mouth and oral cavity before and ... possess additional wellness benefits. KissSafe’s proprietary prevent-tech will ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2
... LINDA, Calif., Feb. 2 Loma Linda ... "Baby-Friendly" designation over the weekend for its efforts ... skills needed to successfully initiate and continue breastfeeding ... in the Nation to be awarded this status. ...
... Pa., Feb. 2 Employers spend more than $13 billion ... - dubbed the world,s number one health threat by the ... are more prone to injury and accidents and incur higher ... a guidepost to help employers address this issue. Health ...
... The U.S. Department of Health and Human ... of interoperability standards developed by the Healthcare ... produces "Interoperability Specifications" - documents that harmonize and ... interoperability of electronic health records and help support ...
... Pet advocates are encouraging,pet owners to focus on their ... Month this February. And it appears more Americans ... saw claims,for illnesses related to oral-health increase 179 percent ... pet owners don,t place as much emphasis on dental ...
... the role of hormone use on the risk of ... progesterone increases the risk of both ductal and lobular ... "safe" period for the use of estrogen and progesterone; ... observed in long-term past users of hormone replacement therapy ...
... Factor in Improving Formulary Placement of Newer ... New Report from HealthLeaders-InterStudy and ... Feb. 2 HealthLeaders-InterStudy and Fingertip Formulary ... pharmacy directors expect to reimburse both Bristol-Myers ...
Cached Medicine News:Health News:LLUCH is First Children's Hospital in Nation to Receive 'Baby-Friendly' Designation 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 2Health News:Health Advocate Releases Obesity White Paper: Strategies and Programs to Reduce Obesity in the Workplace 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:Pet Dental Claims Skyrocket 2Health News:Study identifies potential 'safe period' for hormone replacement use 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 2Health News:Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes 3
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
Medicine Products: